Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard A Burris

Showing results (71-80 of 247) with videos related to

Pageof 25
Sort By:
Clinical Advances in Hematology & Oncology : H&O|May 12, 2011
A pilot study of adjuvant doxorubicin and cyclophosphamide followed by paclitaxel and sorafenib in women with node-positive or high-risk early-stage breast cancerDavid R Spigel, John D Hainsworth, Howard A Burris, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 28, 2010
Phase II study of biweekly pemetrexed and gemcitabine in patients with previously untreated advanced non-small cell lung cancerDavid R Spigel, John D Hainsworth, John H Barton, et al.
Investigational New Drugs|March 26, 2013
A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumorsShubham Pant, Howard A Burris, Kathleen Moore, et al.
Cancer Chemotherapy and Pharmacology|April 11, 2016
A phase I dose escalation study of NK012, an SN-38 incorporating macromolecular polymeric micelleHoward A Burris, Jeffrey R Infante, F Anthony Greco, et al.
Journal of Oncology Practice|September 12, 2019
Patient Navigation in Cancer: The Business Case to Support Clinical NeedsRonald M Kline, Gabrielle B Rocque, Elizabeth A Rohan, et al.
Clinical Breast Cancer|November 26, 2009
Phase II trial of docetaxal plus imatinib mesylate in the treatment of patients with metastatic breast cancerDenise A Yardley, Howard A Burris, Tiffanie Markus, et al.
Cancer Chemotherapy and Pharmacology|May 14, 2014
Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumorsJohanna C Bendell, David S Hong, Howard A Burris, et al.
Cancer Investigation|August 10, 2010
A phase II trial of vinflunine as monotherapy or in combination with trastuzumab as first-line treatment of metastatic breast cancerDenise A Yardley, Michael McCleod, Fred Schreiber, et al.
Cancer Chemotherapy and Pharmacology|June 12, 2017
TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignanciesHoward A Burris, C D Kurkjian, L Hart, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 31, 2009
Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancerDavid R Spigel, F Anthony Greco, John D Zubkus, et al.
Pageof 25

Showing results (71-80 of 247) with videos related to

Sort By:
Pageof 25
Clinical Advances in Hematology & Oncology : H&O|May 12, 2011
A pilot study of adjuvant doxorubicin and cyclophosphamide followed by paclitaxel and sorafenib in women with node-positive or high-risk early-stage breast cancerDavid R Spigel, John D Hainsworth, Howard A Burris, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 28, 2010
Phase II study of biweekly pemetrexed and gemcitabine in patients with previously untreated advanced non-small cell lung cancerDavid R Spigel, John D Hainsworth, John H Barton, et al.
Investigational New Drugs|March 26, 2013
A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumorsShubham Pant, Howard A Burris, Kathleen Moore, et al.
Cancer Chemotherapy and Pharmacology|April 11, 2016
A phase I dose escalation study of NK012, an SN-38 incorporating macromolecular polymeric micelleHoward A Burris, Jeffrey R Infante, F Anthony Greco, et al.
Journal of Oncology Practice|September 12, 2019
Patient Navigation in Cancer: The Business Case to Support Clinical NeedsRonald M Kline, Gabrielle B Rocque, Elizabeth A Rohan, et al.
Clinical Breast Cancer|November 26, 2009
Phase II trial of docetaxal plus imatinib mesylate in the treatment of patients with metastatic breast cancerDenise A Yardley, Howard A Burris, Tiffanie Markus, et al.
Cancer Chemotherapy and Pharmacology|May 14, 2014
Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumorsJohanna C Bendell, David S Hong, Howard A Burris, et al.
Cancer Investigation|August 10, 2010
A phase II trial of vinflunine as monotherapy or in combination with trastuzumab as first-line treatment of metastatic breast cancerDenise A Yardley, Michael McCleod, Fred Schreiber, et al.
Cancer Chemotherapy and Pharmacology|June 12, 2017
TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignanciesHoward A Burris, C D Kurkjian, L Hart, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 31, 2009
Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancerDavid R Spigel, F Anthony Greco, John D Zubkus, et al.
Pageof 25